First, the authors showed, using 186 patients from the Younger MCL cohort, that the presence of KMT2D mutations was associated with a worse OS (p = 0.002); the authors then went on to show that KMT2D plus TP53 mutations/deletions cumulatively had a worse OS (p < 0.0001). The gene discussed is TP53; the disease is mantle cell lymphoma.